Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Cancer Discov. 2012 Dec 14;3(1):82–95. doi: 10.1158/2159-8290.CD-12-0404

Figure 3. Treatment of Eμ-Myc mice with everolimus does not reduce MYC expression or activity in vivo.

Figure 3

Age-matched wild-type littermate control mice (WT), premalignant Eμ-Myc mice treated with placebo for 2 weeks and premalignant Eμ-Myc mice treated with everolimus for 2 weeks were sacrificed and purified B-cells were obtained from the bone marrow and spleen. (A) Expression of MYC and P-RPS6 by Western blotting in purified B220+ B-cells from the bone marrow (left) and spleen (right) of a WT, a placebo-treated transgenic mouse (TG) and three everolimus-treated TG mice. Actin was used as a loading control. Full-length blots are presented in Supplementary Fig. S12. Transcript abundance by qRT-PCR of the MYC target genes ODC1, and UBTF in B220+ cells from the bone marrow (B) and spleen (C) of WT (n=3), placebo-treated transgenic (n=5) and everolimus-treated transgenic mice (n=7). mRNA expression levels were corrected for the expression of ubiquitin B and normalized to expression in WT controls. Data shown is the average ± SEM.